Trait Biosciences Inc.

VANCOUVER, A1 · Founded 2017 · Biotech · Private

Water-soluble cannabinoid powders for precise, consistent dosing

Claim this profile

Follows are private to you and power your alerts

Updated · traitbio.com

Sector
Biotech
Headquarters
VANCOUVER, A1
Founded
2017
Latest Form D
$3.7M, Sep 2023
Total capital
$24.5M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$24.5M
7 Form D · last Sep 2023
37 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
12
28 pending · first 2019
Rank in peer group#6 of 54

Capital timeline

20192020202120222023FEDERAL ↑EQUITY ↓Cumulative $24.5M1st Form D$7.6M2nd Form D$12.1M3rd Form D$619K7th Form D$3.7M
20192020202120222023FEDERAL ↑EQUITY ↓Cumulative $24.5M2nd Form D$12.1M

Latest events

  • Private capital raisedForm D · SEC · 7th filing$3.7M
  • Private capital raisedForm D · SEC · 6th filing$102K
  • Private capital raisedForm D · SEC · 5th filing$230K
  • Private capital raisedForm D · SEC · 4th filing$210K
  • Private capital raisedForm D · SEC · 3rd filing$619K
  • Private capital raisedForm D · SEC · 2nd filing$12.1M
  • Private capital raisedForm D · SEC · 1st filing$7.6M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 54 peers

Line = median

Biotech · Material

  • Granted patents#6 · top 11%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • Richard Thomas SayreResearcherExecutive Officer, PromoterLinked by 3 patents
  • Andrew Templeton HunterExecutive OfficerNamed in SEC Form D filings
  • Aristobulo Thomas LoaizaExecutive OfficerNamed in SEC Form D filings
  • David Templeton RosenthalDirectorNamed in SEC Form D filings
  • David William SmalleyExecutive OfficerNamed in SEC Form D filings
  • Eugene Allan HodgsonExecutive OfficerNamed in SEC Form D filings
Show all 18 people
  • Hanny David KanafaniExecutive OfficerNamed in SEC Form D filings
  • Jay Templeton SweeneyExecutive OfficerNamed in SEC Form D filings
  • Joseph David Del MoralDirectorNamed in SEC Form D filings
  • Kimberly Ann LandryExecutive OfficerNamed in SEC Form D filings
  • Michael Bruce HarrisonExecutive Officer, Director, PromoterNamed in SEC Form D filings
  • Peter J. McDonoughExecutive Officer, DirectorNamed in SEC Form D filings
  • Rebecca Thomas WhiteExecutive OfficerNamed in SEC Form D filings
  • Richard Todd DeRoseExecutive OfficerNamed in SEC Form D filings
  • Ronald E. DeutschExecutive OfficerNamed in SEC Form D filings
  • Ronan David LevyDirectorNamed in SEC Form D filings
  • Tawanda Thomas ZidengaExecutive OfficerNamed in SEC Form D filings
  • Tichafa Regus Ignatius MunyikwaExecutive OfficerNamed in SEC Form D filings

What it has protected

USPTO · 12 granted of 40
Show all 40 patent records

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .